Amgen-Onyx deal swirls with intrigue, strategy

Amgen Inc. cut $9 off a $130-per-share offer after Onyx Pharmaceuticals Inc. wouldn't unblind data from a late-stage study of the potential cancer blockbuster drug Kyprolis, according to a Securities and Exchange Commission filing Tuesday...